Skip to content
Investors Dashboard
Contact
TwitterFacebookInstagramLinkedinYouTube
  • English
  • Spanish
TwitterFacebookInstagramLinkedinYouTube
  • English
  • Spanish
Pharmamar S.A
Pharmamar S.A.
Pharmamar S.APharmamar S.A
  • About PharmaMar
    • Senior Management
    • Management Team PharmaMar
    • Board of directors
    • Other Business
    • PharmaMar in the World
    • Corporate Responsibility
    • Our History
  • Patients
    • Therapeutic Indications
    • Collaboration with Patient Associations
    • Clinical trial
  • Products
    • YONDELIS®
    • Lurbinectedin
  • Science & Innovation
    • R&D and Innovation
    • Virology Unit
      • Our Vision
      • Molecular Pharmacodynamics
      • COVID-19, Clinical Development
      • COVID-19, Translational Strategy
    • Oncology Pipeline
    • Cofinanced Projects
    • Collaboration with Scientific Associations
    • Publications
    • Mechanisms of Action
    • Medical meeting presentations
  • Shareholders and Investors
    • Financial Information
      • Annual Reports
      • Interim financial information
      • Financial Statements (Zeltia)
      • Average Period of Payment to Suppliers
    • Notifications sent to CNMV
    • Share Information
      • Share Performance
      • Shares Outstanding
      • Dividends
      • Significant Shareholding & Company Owned-Stock
      • Analysts
    • Debt Obligations
    • Presentations
    • General Shareholders Meetings
    • Corporate Governance
      • Corporate Bylaws
      • General Shareholders’ Meeting Regulations
      • Shareholder Agreements
      • Board of Directors
      • Board of Directors Regulation
      • Annual Report on Corporate Governance
      • Annual Director Remuneration Report
      • Board Committees
      • Internal Regulation Governing Conduct
      • Director Selection Policy
    • Contact
    • Merger PharmaMar-Zeltia
    • General Policy of Communication
    • Sustainability Policy
    • Director’s Compensation Policy
  • Newsroom
    • Press Releases
    • Events calendar
    • Multimedia
      • Videos
      • Infographics
    • Medical meeting presentations
  • Careers
    • Benefits
    • Send us your CV
  • Privacy Policy newsletter
  • Pharmacovigilance
  • Contact
  • Disclaimer
  • Lurbinectedin
  • Inside Information / Other relevant information
  • Our Vision
  • Molecular Pharmacodynamics
  • COVID-19, Clinical Development
  • COVID-19, Translational Strategy
  • About Pharmamar
  • Shareholders and Investors
  • Legal Notice
  • Human Resources
  • Science & Innovation
  • en User Dashboard
  • en User Login
  • Newsroom
  • Patients
  • Pharmamar Home – 2
  • Cookies Policy
  • Privacy Policy
  • About PharmaMar
  • Subscribe to our Distribution List
  • User Dashboard
  • User Login
  • YONDELIS®
  • About PharmaMar
    • Senior Management
    • Management Team PharmaMar
    • Board of directors
    • Other Business
    • PharmaMar in the World
    • Corporate Responsibility
    • Our History
  • Patients
    • Therapeutic Indications
    • Collaboration with Patient Associations
    • Clinical trial
  • Products
    • YONDELIS®
    • Lurbinectedin
  • Science & Innovation
    • R&D and Innovation
    • Virology Unit
      • Our Vision
      • Molecular Pharmacodynamics
      • COVID-19, Clinical Development
      • COVID-19, Translational Strategy
    • Oncology Pipeline
    • Cofinanced Projects
    • Collaboration with Scientific Associations
    • Publications
    • Mechanisms of Action
    • Medical meeting presentations
  • Shareholders and Investors
    • Financial Information
      • Annual Reports
      • Interim financial information
      • Financial Statements (Zeltia)
      • Average Period of Payment to Suppliers
    • Notifications sent to CNMV
    • Share Information
      • Share Performance
      • Shares Outstanding
      • Dividends
      • Significant Shareholding & Company Owned-Stock
      • Analysts
    • Debt Obligations
    • Presentations
    • General Shareholders Meetings
    • Corporate Governance
      • Corporate Bylaws
      • General Shareholders’ Meeting Regulations
      • Shareholder Agreements
      • Board of Directors
      • Board of Directors Regulation
      • Annual Report on Corporate Governance
      • Annual Director Remuneration Report
      • Board Committees
      • Internal Regulation Governing Conduct
      • Director Selection Policy
    • Contact
    • Merger PharmaMar-Zeltia
    • General Policy of Communication
    • Sustainability Policy
    • Director’s Compensation Policy
  • Newsroom
    • Press Releases
    • Events calendar
    • Multimedia
      • Videos
      • Infographics
    • Medical meeting presentations
  • Careers
    • Benefits
    • Send us your CV

Daily Archives: 26 August, 2019

You are here:
  1. Home
  2. 2019
  3. August
  4. 26

PharmaMar enters into a new licensing agreement with Janssen for Yondelis®

Press ReleaseBy admin26 August, 2019

R&D: new licenses, patents and registered trademarks

CNMV_ESBy admin26 August, 2019
 Dream-Theme — truly premium WordPress themes
Sobre PharmaMar
Go to Top
We use our own and third-party cookies in order to collect statistical information and to ensure the best experience on our site. If you want to accept them, click I agree.I agreeI do not acceptPrivacy policy
You can revoke your consent any time using the Revoke consent button.Revoke consent